tbuckley/cabot-search huggingface dataset:
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations
Authors: Abner Louissaint, Kristian T. Schafernak, Julia T. Geyer, Alexandra E. Kovach, Mahmoud Ghandi, Dita Gratzinger, Christine G. Roth, Christian N. Paxton, Sunhee Kim, Chungdak Namgyal, Ryan Morin, Elizabeth A. Morgan, Donna S. Neuberg, Sarah T. South, Marian H. Harris, Robert P. Hasserjian, Ephraim P. Hochberg, Levi A. Garraway, Nancy Lee Harris, David M. Weinstock
Journal: Blood (2016)
The Role Of Epithelial To Mesenchymal Transition In The Remodeling Of Lung Injury Induced By Acute Graft-Versus-Host Disease
Authors: Meiqing Wu, Can Liu, Ke Zhao, Xiuli Wu, Yu Zhang, Zhiping Fan, Qian Fan, Changxin Yin, Zhongxin Zheng, Zhengshan Yi, Qifa Liu
Journal: Blood (2013)
Ageing and smoking contribute to plasma surfactant proteins and protease imbalance with correlations to airway obstruction
Authors: Helen Ilumets, Witold Mazur, Tuula Toljamo, Noora Louhelainen, Pentti Nieminen, Hideo Kobayashi, Nobuhisa Ishikawa, Vuokko Kinnula
Journal: European Respiratory Journal (2011)

Background: A significant number of young people start smoking at an age of 13-15, which means that serious smoking-evoked changes may have been occurred by their twenties. Surfactant proteins (SP) and matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) have been linked to cigarette smoke induced lung remodelling and COPD. However, the level of these proteins has not been examined during ageing or in young individuals with short smoking histories.

Methods: Plasma levels of SP-A, SP-D, MMP-9, and TIMP-1 were measured by EIA/ELISA from young (18-23 years) non-smoking controls (YNS) (n=36), smokers (YS) (n=51), middle aged/elderly (37-77 years) non-smoking controls (ONS) (n=40), smokers (OS) (n= 64) (FEV1/FVC >0.7 in all subjects) and patients with COPD (n=44, 35-79 years).

Results: Plasma levels of SP-A increased with age and in the older group in relation to smoking and COPD. Plasma SP-D and MMP-9 levels did not change with age but were elevated in OS and COPD as compared to ONS. The TIMP-1 level declined with age but increased in chronic smokers when compared to ONS. The clearest correlations could be detected between plasma SP-A vs age, pack years and FEV1/FVC. The receiver operating characteristic (ROC) curve analysis revealed SP-A to be the best marker for discriminating between patients with COPD and the controls (area under ROC curve of 0.842; 95% confidence interval, 0.785-0.899; p<0.001).

Conclusions: Age has a significant contribution to potential markers related to smoking and COPD; SP-A seems to be the best factor in differentiating COPD from the controls.
Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: Early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid tumors.
Authors: Herbert Hurwitz, John D. Hainsworth, Charles Swanton, Edith A. Perez, Christopher Sweeney, Howard A. Burris, David Spigel, Funda Meric-Bernstam, Donald K Strickland, Larry Leon, Melissa Brammer, Mary Stanley Beattie, Ron Bose
Journal: Journal of Clinical Oncology (2016)

653 Background: Next-generation sequencing often reveals potentially actionable molecular alterations; however, data on approved targeted therapies in non-indicated tumors are limited. MyPathway (NCT02091141) evaluates agents targeting the HER2, EGFR, BRAF, or Hedgehog (Hh) pathways in tumors for which these therapies are not currently indicated. Here, we present early response data for patients with GI tumors. Methods: Eligible patients had metastatic tumors with potentially actionable genomic alterations, identified by a CLIA-certified lab, and progression on standard therapy. Based on the identified alteration, patients received standard doses of trastuzumab + pertuzumab (HER2), erlotinib (EGFR), vemurafenib (BRAF), or vismodegib (Hh). Response was evaluated by the investigator using RECIST v1.1. Results: As of Aug 21, 2015, 96 patients had enrolled, 36 of whom (38%) had GI tumors with the following alterations: HER2 (n=28 [22 amplifications, 5 activating mutations, 1 both]), BRAF (n=4), Hh (n=2 [2 PTCH-1 mutations]), and EGFR (n=2). Patients had a median of 4 (range, 1–8) prior lines of therapy. Tumor types and interim best response data are shown below. Among all evaluable patients with GI tumors (n=26), 5 have had a PR to targeted therapy (duration 3–10+ months). Conclusions: Targetable molecular alterations were found in a variety of GI tumors, resulting in clinical benefit from targeted treatments that would not have otherwise been realized. These early results support this molecular testing strategy. Accrual to the trial continues; based on activity observed, the HER2-positive colorectal cancer cohort will be expanded to ≥30 patients. Additional data will be presented at the meeting. Clinical trial information: NCT02091141. [Table: see text]
P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer
Authors: Taieb Julien, Di Bartolomeo Maria, Cubillo Antonio, Gurtler Jayne, Wilbur Deborah, Xiong Huiling, Zhang Jenny, Cuillerot Jean-Marie, Boku Narikazu, Moehler Markus
Journal: Annals of Oncology (2016)
RTRB-23SENSITIVITY ANALYSIS OF PERMITTIVITY AND CONDUCTIVITY ON ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA
Authors: Edwin Lok, Van Hua, Eric T. Wong
Journal: Neuro-Oncology (2015)

BACKGROUND: The NovoTTF Therapy device uses two pairs of arrays to deliver frequency-tuned alternating electric fields at 200 kHz to treat recurrent glioblastoma. Although its efficacy is equivalent to chemotherapies, the precise distribution of the electric fields within the brain remains poorly understood. METHODS: We performed computerized simulation to determine the electric field distribution inside a patient's brain with a right parietal recurrent glioblastoma, using co-registered post-gadolinium T1-weighted, T2 and MP RAGE MRI images together with pre-specified relative permittivity and conductivity values for each of the cerebral structures. RESULTS: We found higher field strength at the scalp surface, ventricular horns and the medial surface of the tumor. Because the mass density and charges may vary among tumors, particularly when there is variation on the cystic make-up of the necrotic tumor, we performed a sensitivity analysis to investigate the relative contribution of permittivity and conductivity parameters to changes in the electric field distribution. Within the solid portion of the gross tumor volume (GTV), we found no variation in electric field strength from changes in permittivity from 0.001-10,000, mean electric field strength from 81.156 to 78.854 V/m, but marked variation from changes in conductivity from 0.001-100 S/m, mean electric field strength from 131.22 to 1.1463 V/cm. Within the necrotic core of the GTV, we also found no variation in electric field strength from changes in permittivity from 0.001-10,000, mean electric field strength from 39.456 to 40.180 V/m, but again marked variation from changes in conductivity from 0.001-100 S/m, mean electric field strength from 43.074 to 7.2933 V/cm. CONCLUSIONS: The results indicate that conductivity of the tumor plays a greater role than permittivity in the electric field distribution from NovoTTF Therapy.
“Bottle Brush Sign”—Spinal Meningeal Disease on 18F-FDG PET-CT Scan
Authors: Saima Riaz, Fozia Naz, Humayun Bashir, Imran Khalid Niazi
Journal: Clinical Nuclear Medicine (2016)

A 30-year-old man with a history of stage IV AE diffuse large cell lymphoma of left proximal humerus presented with new onset lower limb weakness at completion of chemotherapy. The 18F-FDG PET-CT scan showed increased intraspinal uptake from T12 to S1 vertebrae with unique "bottle brush" appearance in keeping with spinal meningeal disease. The leptomeningeal disease was further confirmed on correlative MRI scan.
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Authors: Anusha Kalbasi, Chad Komar, Graham M. Tooker, Mingen Liu, Jae W. Lee, Whitney L. Gladney, Edgar Ben-Josef, Gregory L. Beatty
Journal: Clinical Cancer Research (2016)

Local tumor growth is a major cause of morbidity and mortality in nearly 30% of patients with pancreatic ductal adenocarcinoma (PDAC). Radiotherapy is commonly used for local disease control in PDAC, but its efficacy is limited. We studied the impact of selectively intervening on radiotherapy-induced inflammation as an approach to overcome resistance to radiotherapy in PDAC.PDAC cell lines derived from primary pancreatic tumors arising spontaneously in KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx-1 Cre mice were implanted into syngeneic mice and tumors were focally irradiated using the Small Animal Radiation Research Platform (SARRP). We determined the impact of depleting T cells and Ly6C+ monocytes as well as inhibiting the chemokine CCL2 on radiotherapy efficacy. Tumors were analyzed by flow cytometry and IHC to detect changes in leukocyte infiltration, tumor viability, and vascularity. Assays were performed on tumor tissues to detect cytokines and gene expression.Ablative radiotherapy alone had minimal impact on PDAC growth but led to a significant increase in CCL2 production by tumor cells and recruitment of Ly6C+CCR2+ monocytes. A neutralizing anti-CCL2 antibody selectively inhibited radiotherapy-dependent recruitment of monocytes/macrophages and delayed tumor growth but only in combination with radiotherapy (P < 0.001). This antitumor effect was associated with decreased tumor proliferation and vascularity. Genetic deletion of CCL2 in PDAC cells also improved radiotherapy efficacy.PDAC responds to radiotherapy by producing CCL2, which recruits Ly6C+CCR2+ monocytes to support tumor proliferation and neovascularization after radiotherapy. Disrupting the CCL2-CCR2 axis in combination with radiotherapy holds promise for improving radiotherapy efficacy in PDAC. Clin Cancer Res; 23(1); 137-48. ©2016 AACR.
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
Authors: A Strangfeld, A Richter, B Siegmund, P Herzer, K Rockwitz, W Demary, M Aringer, Y Meißner, A Zink, J Listing
Journal: Annals of the Rheumatic Diseases (2016)

Objective To investigate the risk of developing lower intestinal perforations (LIPs) in patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ). Methods In 13 310 patients with RA observed in the German biologics register R heumatoid A rthritis: O b servation of Bi ologic T herapy, 141 serious gastrointestinal events possibly associated with perforations were reported until 31 October 2015. All events were validated independently by two physicians, blinded for treatment exposure. Results 37 LIPs (32 in the colon/sigma) were observed in 53 972 patient years (PYs). Only two patients had a history of diverticulitis (one in TCZ). Age, current/cumulative glucocorticoids and non-steroidal anti-inflammatory drugs were significantly associated with the risk of LIP. The crude incidence rate of LIP was significantly increased in TCZ (2.7/1000 PYs) as compared with all other treatments (0.2−0.6/1000 PYs). The adjusted HR (ref: conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs)) in TCZ was 4.48 (95% CI 2.0 to 10.0), in tumour necrosis factor-α inhibitor (TNFi) 1.04 (0.5 to 2.3) and in other biologic DMARDs 0.33 (0.1 to 1.4). 4/11 patients treated with TCZ presented without typical symptoms of LIP (acute abdomen, severe pain). Only one patient had highly elevated C reactive protein (CRP). One quarter of patients died within 30 days after LIP (9/37), 5/11 under TCZ, 2/13 under TNFi and 2/11 under csDMARD treatment. Conclusions The incidence rates of LIP under TCZ found in this real world study are in line with those seen in randomised controlled trials of TCZ and higher than in all other DMARD treatments. To ensure safe use of TCZ in daily practice, physicians and patients should be aware that, under TCZ, LIP may occur with mild symptoms only and without CRP elevation.
European Registry for Low Risk and Intermediate-1 Risk MDS: Base Line Report On First 400 Registered Patients.
Authors: T. M. de Witte, Alex Smith, Jackie Droste, Pierre Fenaux, Argyris Symeonidis, Eva Hellstrom-Lindberg, Guillermo Sanz, Jaroslav Cermak, Otilia Georgescu, Ulrich Germing, Marius MacKenzie, Reinhard Stauder, Odile Beyne Rauzy, David T. Bowen
Journal: Blood (2009)
Proton Pump Inhibitors and Dementia Incidence
Authors: Long Nguyen, Chin Hur
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Comparison of Intensive Chemotherapy (CHT), Allogeneic (ALLO) or Autologous (AUTO) Stem Cell Transplantation (SCT) as Post-Remission Treatment for Adult Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL). Final Results of the PETHEMA ALL-93 Trial.
Authors: Josep-Maria Ribera, Albert Oriol, Concepcion Bethencourt, Ricardo Parody, Jesus-Maria Hernandez-Rivas, Maria-Jose Moreno, Eloy Del Potro, Mar Tormo, Concepcion Rivas, Joan Besalduch, Miguel-Angel Sanz, Jesus Arias, Javier Fernandez-Calvo, Jose-Maria Moraleda, Javier Bueno, Evarist Feliu, Juan-Jose Ortega
Journal: Blood (2004)
A phase III randomized, double-blind, placebo-controlled study of pegfilgrastim in first-line colorectal cancer patients receiving bevacizumab and either FOLFOX or FOLFIRI.
Authors: T. Pinter, J. Decaestecker, L. Choi, M. Mo, S. Whittaker, T. A. Rado, L. B. Holt
Journal: Journal of Clinical Oncology (2010)

TPS326 Background: Accumulating data indicate that adding biologic or targeted agents to standard chemotherapy (CT) may result in increased rates of clinically significant neutropenia. However, few well-designed adequately powered trials have evaluated this. Health care providers may be unaware of the additional toxicity of these agents and thus, patients (pts) may be exposed to an increased risk of neutropenia-related events. The primary objective of this randomized, double-blind, placebo (PBO)-controlled, phase III study is to evaluate the efficacy of pegfilgrastim as compared with PBO in reducing the incidence of grade 3/4 febrile neutropenia (FN) in pts with newly diagnosed, locally advanced or metastatic colorectal cancer (CRC) treated with bevacizumab (bev) and either FOLFOX or FOLFIRI. Secondary objectives include estimating the effects of pegfilgrastim on the efficacy of bev and CT compared with PBO as evaluated by overall survival (OS), progression-free survival, and objective response rate. Methods: Pts will be randomized 1:1 to receive pegfilgrastim or PBO once-per-CT cycle (up to 4 cycles), approximately 24 hours after CT; stratified by region (North America vs Rest of World), disease stage (locally advanced vs metastatic), and CT type (FOLFOX vs FOLFIRI). The primary efficacy endpoint is the incidence of grade 3/4 FN (defined as a temperature ≥ 38°C [≥ 100.4°F] and absolute neutrophil count [ANC] < 1.0x109/L, where ANC is measured the same day or within a 24-hr window of a temperature ≥ 38°C). The study is designed to have 90% power at a 2-sided significance level of 0.05 to detect a reduction in grade 3/4 FN rate from 9% to 3% (66.7% relative reduction). Radiographic disease assessment will occur after completion of 4 cycles and at 8 weekly intervals until progression. Pts will be followed for OS for up to 5 years. With a planned sample size of 800 pts and up to 5 years of long-term follow-up, this is one of the largest studies conducted in CRC pts to date. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen Amgen, GlaxoSmithKline, Ipsen, Novartis, Roche Amgen Amgen, Novartis, Roche Amgen
Sexual and prevention practices in men who have sex with men in the era of combination HIV prevention: results from the Presse Gays et Lesbiennes survey, France, 2011
Authors: A Velter, L Saboni, C Sommen, P Bernillon, N Bajos, C Semaille
Journal: Eurosurveillance (2015)

Binary file ES_Abstracts_Final_ECDC.txt matches
miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis
Authors: Jianfei Xue, Aidong Zhou, Yamei Wu, Saint-Aaron Morris, Kangyu Lin, Samirkumar Amin, Roeland Verhaak, Gregory Fuller, Keping Xie, Amy B. Heimberger, Suyun Huang
Journal: Cancer Research (2016)

Abstract Malignant glioma is an often fatal type of cancer. Aberrant activation of STAT3 leads to glioma tumorigenesis. STAT3-induced transcription of protein-coding genes has been extensively studied; however, little is known about STAT3-regulated miRNA gene transcription in glioma tumorigenesis. In this study, we found that abnormal activation or decreased expression of STAT3 promotes or inhibits the expression of miR-182-5p, respectively. Bioinformatics analyses determined that tumor suppressor protocadherin-8 (PCDH8) is a candidate target gene of miR-182-5p. miR-182-5p negatively regulated PCDH8 expression by directly targeting its 3′-untranslated region. PCDH8 knockdown induced the proliferative and invasive capacities of glioma cells. Silencing of PCDH8 or miR-182-5p mimics could reverse the inhibitory effect of WP1066, a STAT3 inhibitor, or STAT3 knockdown in vitro and in vivo on glioma progression. Clinically, expression levels of PCDH8 were inversely correlated with those of p-STAT3 or miR-182-5p in glioblastoma tissues. These findings reveal that the STAT3/miR-182-5p/PCDH8 axis has a critical role in glioma tumorigenesis and that targeting the axis may provide a new therapeutic approach for human glioma. Cancer Res; 76(14); 4293–304. ©2016 AACR.
Public health response to a rabid dog in an animal shelter - North Dakota and Minnesota, 2010.
Authors: K. Kruger, T. Miller, M. Feist, S. Keller, B. Carlson, R. Klockmann, J. Scheftel, C. Rupprecht, J. R. Cope, B. Petersen
Journal: MMWR Morbidity and Mortality Weekly Report (2010)
P-028 Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)
Authors: J. Souglakos, Z. Saridaki, N. Gouges, A. Voutsina, M. Tzardi, A. Kalikaki, M. Sfakianaki, A. Athanasiadis, E. Xynos, I. Boukovinas
Journal: Annals of Oncology (2016)
Lesions of the Gastric Mucosa in Strong Strain NHO Mice&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Henry S. Kaplan, M. D.
Journal: JNCI Journal of the National Cancer Institute (1949)

Journal Article Lesions of the Gastric Mucosa in Strong Strain NHO Mice Get access Henry S. Kaplan, M. D. Henry S. Kaplan, M. D. Department of Radiology, Stanford University School of Medicine, San Francisco Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 2, October 1949, Pages 407–421, https://doi.org/10.1093/jnci/10.2.407 Published: 01 October 1949
P-168 Retrospective comparison of efficacy and safety of docetaxel and weekly-paclitaxel as 2nd-line chemotherapy for patients with unresectable or recurrent esophageal cancer
Authors: H. Nakatsumi, Y. Komatsu, K. Sawada, T. Muranaka, Y. Kawamoto, S. Yuki, N. Sakamoto
Journal: Annals of Oncology (2016)
Distribution and Patterns of Industry-Related Payments to Oncologists in 2014
Authors: Deborah C. Marshall, Beverly Moy, Madeleine E. Jackson, Tim K. Mackey, Jona A. Hattangadi-Gluth
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: Industry-physician collaboration is critical for anticancer therapeutic development, but financial relationships introduce conflicts of interest. We examined the specialty variation and context of physician payments and ownership interest among oncologists. Methods: We performed a population-based multivariable analysis of 2014 Open Payments reports of industry payments to US physicians matched to physician and practice data, including sex, specialty, practice location, and sole proprietor status. Payment data were aggregated per physician and compared by specialty (medical, radiation, surgical, and nononcology), and practice location linked with spending level (low, average, and high). Primary outcomes included likelihood, mean annual amount, and number of general payments. Secondary outcomes included likelihood of holding ownership interests and receipt of royalty/license payments. Estimates for each outcome were determined using multivariable models, including logistic regression for likelihood and linear regression with gamma distribution and log-link for value, adjusted for physician specialty, sex, sole proprietor status, and practice spending. All statistical tests were two-sided. Results: In 2014, there were 883 438 physicians, including 22 712 oncologists, licensed to practice in the United States. Among oncology specialties, 52.4% to 63.0% of physicians received a general payment in 2014, totaling $76 million, $4 million, and $5 million to medical, radiation, and surgical oncology, respectively. The median annual per-physician payment to medical oncologists was $632 (IQR = 136–2500), compared with $124 (IQR = 39–323) in radiation oncology and $250 (IQR = 84–1369) in surgical oncology. After controlling for physician and practice characteristics, oncologists were 1.09 to 1.75 times as likely to receive a general payment compared with nononcologists (overall P < .001). There was a 67.6% difference (95% confidence interval [CI] = 63.6 to 71.5, P < .001) in the mean annual value of payments between medical oncology and nononcology specialties (vs −92.7%, 95%CI = −100.2 to −85.0, P < .001] for radiation oncology). Medical and radiation oncologists were more likely to hold ownership interest (adjusted OR = 3.72, 95% CI = 3.22 to 4.27, and 2.27, 95% CI = 1.65 to 3.03, respectively, P < .001 both comparisons). Conclusions: In 2014, industry-oncologist financial relationships were common, and their impact on oncology practice should be further explored.
Uremia
Authors: John P. Merrill, Constantine L. Hampers
Journal: New England Journal of Medicine (1970)

THIS review will deal primarily with progress in our knowledge of the pathophysiology of the uremic syndrome. It will touch only briefly the background on which this progress has been made, and the comments on therapy will be limited to the newer aspects of uremia to which they are pertinent. Background material is available in previously published reviews.1 2 3 4 5 Renal Function in UremiaAn explanation for the abnormalities in renal function and the composition of the urine that occur with marked loss of functioning renal tissue was first proposed more than 15 years ago, when it was suggested that the few . . .